Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Carotuximab · DE-122, TRC-105

Monoclonal antibody · Antagonist of endoglin (CD105) (ENG) · developed by Tracon Pharmaceuticals

Phase 2 Most advanced trial
1 Registered trials

What is Carotuximab?

Carotuximab is a human/murine chimeric monoclonal antibody that binds endoglin (CD105), a TGF beta-1 accessory receptor highly expressed on tumor vessel endothelial cells. By binding endoglin it may inhibit tumor angiogenesis and reduce tumor cell proliferation. It is studied in castration-resistant prostate cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
DE-122, TRC-105
Drug type
Monoclonal antibody
Targets
endoglin (CD105) (ENG)
Mechanism
Antagonist of endoglin (CD105) (ENG)
Pathways
angiogenesis, TGF beta signaling
Therapy area
Oncology
Developer
Tracon Pharmaceuticals Inc.
In trials of
KAPA
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
YB2EWE6139

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05534646 Phase 2 Castration-resistant Prostate Cancer Recruiting KAPA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Castration-resistant Prostate Cancer

Sources

Updated Oct 18, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.